Bio Wink SC
Bio Wink reported total assets of 106,514 € at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Jan 2026).
The score of Bio Wink shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -23 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Bio Wink's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 11,659 € | ||||
| Equity | 38,779 € | ||||
| Cash | 15,935 € | ||||
| EBITDA | 20,475 € | ||||
| Total assets | 106,514 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 28 Jan 2026
- Year ended 30 Jun 2024filed on 24 Jan 2025
- Year ended 30 Jun 2023filed on 31 Jan 2024
- Year ended 30 Jun 2022filed on 21 Feb 2023
- Year ended 30 Jun 2021filed on 22 Dec 2021
Bio Wink's financial analysis
- Solvency36.4%sector median: 32.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Bio Wink
Bio Wink's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0736.308.291
- VAT number
- BE0736308291
- Peppol
- Registered · 0208:0736308291 · as of 11 Nov 2026
- Legal form
- SC
- Incorporated
- 11 Oct 2019
- Registered office
- 1000 Brussels
- Latest accounts
- 2025 · filed on 28 Jan 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Bio Wink (SC) has been based in Brussels since 2019, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 11,659 € and equity of 38,779 €; its revenue is not published. Its solvency stands at 36.4%, above the median of its sector (32.3%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Bio Wink
Companies in the same business, of comparable size and area, outside its group.
- O'Active Wholesale of pharmaceutical and medical goods Etterbeek · balance sheet 60,121 €
- NBS Scientific Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 152,659 €
- DentalPharma Wholesale of pharmaceutical and medical goods Ostend · balance sheet 228,805 €
- R&B Prestige Import-Export Wholesale of pharmaceutical and medical goods Schaerbeek · balance sheet 212,840 €
- Nature Avenue Wholesale of pharmaceutical and medical goods Lier · balance sheet 105,922 €
- Noreva BE Wholesale of pharmaceutical and medical goods Ghent · balance sheet 99,431 €
- Zabrus Wholesale of pharmaceutical and medical goods Sint-Martens-Latem · balance sheet 119,641 €
- Lopital België Wholesale of pharmaceutical and medical goods Aartselaar · balance sheet 120,231 €
Frequently asked questions about Bio Wink
What is the revenue of Bio Wink?
Bio Wink files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Bio Wink?
In Belgium, the VAT number is the company number prefixed with BE: BE0736308291 for Bio Wink, if the company is VAT-registered. Its company number (CBE) is 0736.308.291.
Where is the registered office of Bio Wink?
According to the CBE register, the registered office of Bio Wink is in 1000 Brussels.
What is the equity of Bio Wink?
At the close of the 2025 financial year, the equity of Bio Wink amounts to 38,779 €, a solvency of 36.4% of total assets.
Who manages Bio Wink?
The register lists 6 active mandates at Bio Wink. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Bio Wink
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →